HBM Holdings (HBM Holdings) Receivables Turnover : 1.63 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. HBM Holdings's Revenue for the six months ended in Dec. 2023 was $48.51 Mil. HBM Holdings's average Accounts Receivable for the six months ended in Dec. 2023 was $29.76 Mil. Hence, HBM Holdings's Receivables Turnover for the six months ended in Dec. 2023 was 1.63.

HBM Holdings Receivables Turnover Historical Data

The historical data trend for HBM Holdings's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Receivables Turnover Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

5.70

10.34

7.96

11.38

3.01

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial						1.87	449.27	3.61	5.73	1.63

Competitive Comparison of HBM Holdings's Receivables Turnover

For the Biotechnology subindustry, HBM Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Receivables Turnover falls into.

HBM Holdings Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

HBM Holdings's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	89.502	/ (	(7.118	+	52.323)	/	2 )
=	89.502	/	29.7205
=	3.01

HBM Holdings's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	48.506	/ (	(7.191	+	52.323)	/	2 )
=	48.506	/	29.757
=	1.63

HBM Holdings (OTCPK:HBMHF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

HBM Holdings Receivables Turnover Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings (HBM Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

02142:Hong Kong

Address

420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire • 01-19-2024